Myasthenia Gravis Research Highlights: AAN 2024
Nicholas Silvestri, MD, of the Univ of Buffalo, provides an overview of the latest myasthenia gravis clinical research presented at AAN 2024.
Related Articles
Fulvestrant Yields No OS Differences Vs Anastrozole in HR+ Breast Cancer
Data show a trend towards a reduced risk of death with fulvestrant vs anastrozole among patients with nonvisceral disease in the phase 3 FALCON trial.
ASTCT Learning Center: 2025 Survivorship SIG Business Meeting
Th is meeting will air on Thursday, January 30 at 3:00 – 4:00 p.m. CT. Drs. Christine Duncan and Catherine Lee, Survivorship SIG Leadership, will…
Nivolumab Plus Ipilimumab Bests Chemo in MSI-H, dMMR Colorectal Cancer – Oncology Nurse Advisor
Progression-free survival was improved among patients who received nivolumab and ipilimumab, and toxicity was generally greater among patients who received chemotherapy.
Non-Invasive Biomarkers: Key to Better Pancreatic Cancer Outcomes
Ajay Goel, PhD, AGAF, discusses how the development and validation of novel non-invasive biomarkers can improve early detection and ultimately impact patient outcomes for patients.
Campaign for Fred Hutch
Thanks to our generous supporters, Fred Hutch is redefining cancer and infectious disease for the next generation. Join us as we look beyond what’s possible…
Cabozantinib Bests Placebo in Extrapancreatic NETs With Primary Tumor Arising in the Gl Tract
A subgroup analysis of the CABINET trial showed that cabozantinib extended PFS vs placebo in extrapancreatic NETs with a primary tumor arising in the GI…
Everolimus Plus Lanreotide Shows Significant Benefits in New Standard in GEP-NET Treatment
Learn about the combination treatment of Everolimus Plus Lanreotide and its effectiveness for patients with advanced GEP-NETs.
Faith and Ingenuity: Bringing the First Oncology Clinical Trial to Trinidad
Researchers share lessons from the first oncology clinical trial in Trinidad and Tobago, which involved a patient named Faith Hill.
